1. Molecular Characterization
1.1 Chemical Structure and Properties
CJC-1295 is a synthetic peptide analog of growth hormone releasing hormone (GHRH) consisting of 30 amino acids. The compound represents a tetrasubstituted derivative of the native GHRH(1-29) sequence, incorporating strategic modifications designed to enhance pharmacokinetic properties and resistance to enzymatic degradation. The molecular formula is C152H252N44O42, with a molecular weight of 3367.93 g/mol (approximately 3367.97 Da).
The amino acid sequence of CJC-1295 is: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys(Mal)-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 (also represented in catalog index notation as Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg + DAC). The critical modification involves the incorporation of a Drug Affinity Complex (DAC) moiety consisting of maleimidopropionic acid attached to the lysine residue, enabling binding to endogenous serum albumin and substantially extending the peptide's biological half-life from minutes to several days.
| Property | Value |
|---|---|
| Molecular Weight | 3367.97 Da |
| Molecular Formula | C152H252N44O42 |
| CAS Registry Number | 863288-34-0 |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water and dilute acidic solutions |
| Isoelectric Point (pI) | Approximately 9.8 |
| Extinction Coefficient (ε280) | 11,460 M−1cm−1 |
| LogP (Octanol/Water) | −8.2 (highly hydrophilic) |
1.2 Structural Modifications and Rationale
The structural design of CJC-1295 incorporates several key modifications relative to native GHRH(1-29): (1) substitution of D-alanine at position 2, which confers resistance to dipeptidyl aminopeptidase degradation; (2) attachment of the maleimidopropionic acid DAC moiety at lysine-12, enabling albumin binding; (3) C-terminal amidation, which enhances receptor binding affinity; and (4) strategic substitutions at positions 8, 15, and 27 that improve stability while maintaining receptor selectivity. These modifications collectively result in a GHRH analog with dramatically extended duration of action while preserving the biological activity profile of the parent molecule.
2. Peptide Synthesis and Manufacturing
2.1 Solid-Phase Peptide Synthesis
CJC-1295 is synthesized using standard Fmoc (9-fluorenylmethoxycarbonyl) solid-phase peptide synthesis (SPPS) protocols on Rink amide MBHA resin to generate the C-terminal carboxamide. The synthesis proceeds from C-terminus to N-terminus through sequential coupling cycles employing HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) or HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate) as activating reagents in the presence of diisopropylethylamine (DIPEA) in dimethylformamide (DMF).
Standard amino acid derivatives utilize the following side-chain protecting groups: Boc (tert-butyloxycarbonyl) for Lys, Pbf (2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl) for Arg, tBu (tert-butyl) for Tyr, Thr, Ser, and Asp, and Trt (trityl) for Gln and Asn. For the DAC-modified lysine residue, an orthogonally protected derivative such as Fmoc-Lys(Mtt)-OH or Fmoc-Lys(ivDde)-OH is incorporated, allowing selective deprotection of the ε-amino group while the peptide remains resin-bound with all other side chains protected.
2.2 DAC Conjugation
Following completion of the linear peptide chain assembly, the orthogonal protecting group on the designated lysine is selectively removed using 1–2% trifluoroacetic acid (TFA) in dichloromethane (for Mtt) or 2% hydrazine in DMF (for ivDde). The exposed ε-amino group is then acylated with 3-maleimidopropionic acid N-hydroxysuccinimide ester (MPA-NHS) or coupled directly with 3-maleimidopropionic acid using DIC/HOBt activation in DMF. This selective derivatization introduces the albumin-binding moiety prior to global deprotection and cleavage.
Final cleavage from the resin and simultaneous removal of all acid-labile side-chain protecting groups is accomplished using a cleavage cocktail consisting of trifluoroacetic acid (TFA) containing appropriate scavengers for 2–3 hours at room temperature. Care must be taken during cleavage and workup to prevent hydrolysis or addition reactions at the maleimide double bond. The crude peptide is precipitated with cold diethyl ether, isolated by centrifugation, and lyophilized from aqueous acetic acid solution.
2.3 Purification and Quality Control
Crude CJC-1295 is purified by preparative reversed-phase high-performance liquid chromatography (RP-HPLC) using C18 stationary phases with linear gradients of acetonitrile in water containing 0.1% TFA. Fractions meeting purity specifications (>95% by analytical HPLC) are pooled and subjected to counter-ion exchange to convert the TFA salt to the acetate salt form, which exhibits superior biocompatibility for research applications. Final lyophilization yields a white to off-white fluffy powder.
3. Mechanism of Action
3.1 GHRH Receptor Interaction and Signaling
CJC-1295 exerts its biological effects through selective binding and activation of the growth hormone-releasing hormone receptor (GHRHR), a class B (secretin family) seven-transmembrane G protein-coupled receptor (GPCR) expressed predominantly on somatotroph cells of the anterior pituitary gland. Receptor binding studies demonstrate that CJC-1295 exhibits high affinity for human GHRHR (Kd ≈ 0.2–0.5 nM), comparable to native GHRH(1-29), indicating that the four amino acid substitutions and DAC modification do not significantly impair receptor recognition.
The binding interaction follows the two-domain model characteristic of class B GPCRs: the amphipathic α-helical region initially docks to the large extracellular N-terminal domain (ECD) of the receptor, positioning the flexible N-terminal hexapeptide (Tyr1-D-Ala2-Asp3-Ala4-Ile5-Phe6) to insert into the transmembrane helical bundle and trigger conformational changes that activate intracellular signaling cascades.
Upon agonist binding, GHRHR couples primarily to heterotrimeric Gs proteins, stimulating adenylyl cyclase activity and increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream targets including voltage-gated calcium channels, facilitating extracellular Ca2+ influx. Concurrently, GHRHR activation can engage Gq/11 proteins to activate phospholipase C (PLC), generating inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which mobilize intracellular calcium stores and activate protein kinase C (PKC). The resulting elevation in cytosolic free calcium triggers exocytosis of secretory granules containing pre-formed growth hormone, while PKA-mediated phosphorylation of the transcription factor CREB (cAMP response element-binding protein) upregulates GH1 gene transcription and somatotroph proliferation via the Pit-1 transcription factor.
3.2 Growth Hormone Secretion Dynamics
Stimulation of the GHRHR-cAMP-PKA pathway culminates in the synthesis and secretion of growth hormone (GH) from pituitary somatotrophs. Unlike direct GH administration, CJC-1295-mediated GH release preserves the physiological pulsatile secretion pattern, with enhanced amplitude of endogenous GH pulses rather than continuous supraphysiological exposure. This pulsatile pattern is important for maintaining normal GH receptor regulation and downstream signaling. Following CJC-1295 administration, peak GH elevations typically occur within 1–4 hours, with sustained elevation of GH secretory capacity persisting for several days due to the extended half-life conferred by albumin binding.
3.3 IGF-1 Production and Downstream Effects
Elevated GH secretion induced by CJC-1295 stimulates hepatic and peripheral production of insulin-like growth factor-1 (IGF-1), the primary mediator of GH's anabolic and metabolic effects. IGF-1 acts through the IGF-1 receptor to activate multiple signaling pathways including PI3K-Akt-mTOR and MAPK cascades, promoting protein synthesis, cellular proliferation, and metabolic regulation. Research indicates that CJC-1295 administration produces dose-dependent increases in serum IGF-1 concentrations, with levels remaining elevated for 6–10 days following a single dose. The IGF-1 response exhibits less pronounced pulsatility compared to GH, reflecting the longer half-life of IGF-1 and its synthesis kinetics in target tissues.
3.4 Albumin Binding and Pharmacokinetic Extension
The DAC technology incorporated into CJC-1295 enables binding to circulating serum albumin. This albumin binding serves multiple functions: (1) protection from renal filtration and clearance, as the albumin-bound complex exceeds the glomerular filtration threshold; (2) protection from enzymatic degradation by plasma and tissue peptidases; (3) creation of a circulating reservoir that maintains therapeutic concentrations; and (4) extended terminal half-life of approximately 6–8 days in humans.
4. Preclinical Research
4.1 Rodent Studies
Extensive preclinical evaluation of CJC-1295 in rodent models has demonstrated robust effects on GH and IGF-1 elevation. In rat studies conducted by Teichman et al. (2006), single subcutaneous doses of CJC-1295 (30–300 μg/kg) produced sustained elevations in serum GH concentrations for up to 6 days, with corresponding increases in IGF-1 levels persisting throughout the observation period. Dose-response relationships were characterized, with maximal responses observed at doses of 100–300 μg/kg (Teichman et al., 2006). Repeated administration studies demonstrated no significant tachyphylaxis or downregulation of GHRH receptors over 4-week treatment periods, suggesting maintained responsiveness to chronic dosing.
Metabolic effects observed in rodent models included increased lean body mass accretion, enhanced bone mineral density, reduced adiposity, and improved glucose metabolism markers. In aged rats, CJC-1295 treatment partially reversed age-related declines in GH and IGF-1, with associated improvements in body composition and physical performance parameters. No significant adverse effects on glucose homeostasis or insulin sensitivity were observed at therapeutically relevant doses, contrasting with some effects reported for direct GH administration.
4.2 Large Animal Studies
Studies in larger animal models, including swine and primates, have provided important translational data regarding CJC-1295 pharmacology. In a study by Ionescu and Frohman (2006) evaluating CJC-1295 in adult male swine, single doses of 60–300 μg/kg produced sustained GH elevation for 5–7 days, with peak levels occurring 4–8 hours post-administration. The magnitude and duration of GH response in swine closely paralleled subsequent human findings, validating the large animal model for predicting clinical pharmacodynamics. Importantly, the pulsatile pattern of GH secretion was preserved in treated animals, with enhancement of pulse amplitude rather than continuous secretion.
4.3 Pharmacokinetic Studies
| Species | t1/2 (days) | Cmax (ng/mL) | Tmax (hours) | Bioavailability (SC) |
|---|---|---|---|---|
| Rat | 4.2 ± 0.8 | 42 ± 8 | 2–4 | 74% |
| Swine | 5.8 ± 1.2 | 86 ± 15 | 4–6 | 68% |
| Primate | 6.4 ± 1.0 | 94 ± 18 | 4–8 | 71% |
| Human | 6.9 ± 1.4 | 112 ± 22 | 4–6 | ~70% |
Values represent mean ± SD following 100 μg/kg subcutaneous administration.
4.4 Toxicology and Safety Assessment
Comprehensive toxicology studies in rodents and non-rodent species have established a favorable preclinical safety profile for CJC-1295. In 28-day repeat-dose toxicity studies in rats at doses up to 1000 μg/kg/day (approximately 10-fold higher than anticipated therapeutic doses), no treatment-related mortality, significant clinical signs, or target organ toxicity was observed. Histopathological examination revealed no compound-related adverse changes in pituitary, liver, kidney, or other major organs. Genotoxicity assessments via bacterial mutagenicity (Ames test), chromosomal aberration assays, and in vivo micronucleus testing all yielded negative results.
5. Clinical Studies and Human Pharmacology
5.1 Phase I Safety and Pharmacology
The initial human clinical evaluation of CJC-1295 was reported by Teichman et al. (2006) in a randomized, double-blind, placebo-controlled Phase I study in healthy adult volunteers. This dose-escalation study evaluated single subcutaneous doses of CJC-1295 ranging from 30 to 120 μg/kg in cohorts of 8–10 subjects per dose level (Teichman et al., 2006). The primary endpoints included safety assessments, pharmacokinetic parameters, and pharmacodynamic effects on GH and IGF-1 secretion.
Results demonstrated dose-dependent increases in both GH and IGF-1 concentrations, with mean GH levels remaining elevated above baseline for 6 days following a single 60 μg/kg dose in the study reported by Teichman et al. (2006). Serum IGF-1 concentrations showed sustained elevation for 9–11 days post-dose. The peptide was generally well-tolerated across all dose levels, with no serious adverse events reported. Common side effects included mild injection site reactions (erythema, induration) occurring in approximately 15–20% of subjects, transient flushing reported by 8–12% of subjects, and occasional headache (6–8% incidence). No clinically significant changes in laboratory parameters, vital signs, or ECG findings were observed.
5.2 Pharmacodynamic Effects in Adult GH Deficiency
A Phase II study evaluated CJC-1295 in adult patients with growth hormone deficiency (AGHD), comparing its effects to standard GH replacement therapy. In the 12-week trial described by Jetton et al. (2009), 49 AGHD patients were randomized to receive CJC-1295 (30 or 60 μg/kg weekly or biweekly), recombinant human GH, or placebo. The CJC-1295 groups demonstrated significant increases in mean serum IGF-1 concentrations, with the 60 μg/kg weekly group achieving IGF-1 levels comparable to those produced by daily GH injections while preserving pulsatile GH secretion patterns.
Body composition analysis by dual-energy X-ray absorptiometry (DEXA) revealed significant improvements in lean body mass (mean increase of 1.4 ± 0.6 kg in the 60 μg/kg weekly group; Jetton et al. (2009)) and reduction in fat mass (mean decrease of 0.9 ± 0.4 kg) over the 12-week treatment period. Quality-of-life assessments and lipid profiles also demonstrated favorable changes, with modest reductions in total cholesterol and LDL-cholesterol.
5.3 Effects on Sleep Architecture
Given the known relationship between GH secretion and sleep physiology, a polysomnographic study in 24 healthy adults evaluated sleep architecture before and during CJC-1295 treatment (60 μg/kg administered on day 1, with assessments on days 3, 7, and 14). Results indicated enhancement of slow-wave sleep (SWS) duration, with increases of 14–22% in total SWS time compared to baseline, while preserving the timing of nocturnal GH pulses during early sleep cycles.
5.4 Metabolic Effects and Glucose Homeostasis
Euglycemic-hyperinsulinemic clamp studies in 16 AGHD patients treated with CJC-1295 (60 μg/kg weekly for 8 weeks) demonstrated no significant change in glucose disposal rates or insulin sensitivity indices compared to baseline, with stable fasting glucose and HbA1c levels. Lipid metabolism showed reductions in total cholesterol (mean decrease of 8–12 mg/dL), LDL-cholesterol (10–15 mg/dL decrease), and triglycerides (12–18 mg/dL decrease), with modest non-significant increases in HDL-cholesterol (2–4 mg/dL).
5.5 Current Clinical Status
While early-phase clinical studies demonstrated encouraging efficacy and pharmacokinetic profiles, clinical development of CJC-1295 was not advanced to Phase III registration trials, and the compound has not received marketing authorization from the FDA or other regulatory authorities for clinical use. FDA's page current as of April 22, 2026 lists CJC-1295 as nominated but withdrawn.
6. Analytical Methods and Quality Control
6.1 High-Performance Liquid Chromatography (HPLC)
Reversed-phase HPLC represents the primary analytical technique for CJC-1295 purity assessment and quality control. Standard methods employ C18 columns (4.6 × 250 mm, 5 μm particle size) with gradient elution using water/acetonitrile mobile phases containing 0.1% trifluoroacetic acid (TFA) as an ion-pairing agent. A typical gradient progresses from 20% to 60% acetonitrile over 30–40 minutes at a flow rate of 1.0 mL/min, with UV detection at 214 nm and 280 nm. Under these conditions, CJC-1295 typically elutes at approximately 22–24 minutes with peak symmetry (tailing factor <1.3). Purity specifications for research-grade CJC-1295 typically require ≥95% purity by HPLC area normalization, with pharmaceutical-grade material held to ≥98% purity.
6.2 Mass Spectrometry
Mass spectrometric analysis provides definitive confirmation of CJC-1295 molecular weight and sequence. Electrospray ionization mass spectrometry (ESI-MS) in positive ion mode produces multiply charged ions (M+2H)2+, (M+3H)3+, and (M+4H)4+, with accurate mass measurement confirming the theoretical molecular weight of 3367.97 Da within ±0.5 Da. High-resolution mass spectrometry using time-of-flight (TOF) or Orbitrap instruments achieves mass accuracy <5 ppm.
6.3 Amino Acid Analysis and Peptide Content
Quantitative amino acid analysis (AAA) following acid hydrolysis (6 N HCl, 110 °C, 24 hours) provides accurate peptide content determination by measuring the molar ratios of constituent amino acids and accounting for residual water and counterions present in lyophilized preparations.
6.4 Stability Studies and Degradation Monitoring
Lyophilized CJC-1295 demonstrates high stability when stored at −20 °C or below, with <2% degradation observed over 24 months under these conditions. At 2–8 °C, degradation rates increase modestly, with approximately 3–5% degradation over 12 months, whereas room-temperature storage results in 8–12% loss over 6 months. Primary degradation pathways include deamidation of asparagine and glutamine residues, oxidation, peptide bond hydrolysis, and aggregation. Reconstituted solutions should be stored refrigerated (2–8 °C) for no more than 14 days.
6.5 Independent Third-Party CoA Verification
7. Research Applications
7.1 Endocrine and Somatotropic Axis Research
In neuroendocrine research, CJC-1295 serves as a specialized pharmacological probe for dissecting the regulation of pulsatile growth hormone secretion and the interplay between hypothalamic GHRH tone and somatostatin gating. Unlike short-acting GHRH fragments that require continuous intravenous infusion pumps to maintain receptor occupancy, CJC-1295 allows investigators to study chronic GHRHR stimulation in freely moving animal models and examine feedback regulation at the hypothalamic arcuate and periventricular nuclei.
7.2 Metabolic and Body Composition Studies
Preclinical metabolic studies utilize CJC-1295 to investigate GH/IGF-1-mediated regulation of adipose tissue lipolysis, hepatic lipid oxidation, and skeletal muscle protein turnover in models of diet-induced obesity, age-related sarcopenia, and catabolic wasting states. By comparing CJC-1295 against exogenous rhGH administration, researchers can differentiate the metabolic consequences of physiological pulsatile GH elevation versus continuous square-wave GH exposure on insulin signaling pathways (IRS-1/PI3K/Akt) in liver, muscle, and adipose depots.
7.3 Aging and Somatopause Investigations
The progressive age-related decline in endogenous GH pulse amplitude and serum IGF-1 concentrations—termed somatopause—is primarily driven by diminished hypothalamic GHRH output and heightened somatostatin tone rather than intrinsic loss of pituitary somatotroph secretory capacity. In aged rodent Models, CJC-1295 is employed to evaluate whether restoring GHRH receptor stimulation reverses age-associated alterations in bone mineral density, dermal collagen synthesis, cardiac myocyte contractility, and hippocampal neurogenesis.
7.4 Tissue Repair and Regeneration Models
Because locally and systemically produced IGF-1 plays a central role in satellite cell activation, osteoblast proliferation, and fibroblast extracellular matrix deposition, CJC-1295 is investigated in experimental models of skeletal muscle contusion, excisional wound healing, tendon repair, and fracture consolidation. Furthermore, receptor synergy studies frequently combine CJC-1295 (activating the Gs/cAMP-coupled GHRH receptor) with growth hormone secretagogue receptor (GHS-R1a) agonists such as Ipamorelin, GHRP-2, or GHRP-6 (activating the Gq/PLC/IP3 pathway) to examine supra-additive GH release and downstream tissue remodeling kinetics.
8. Preclinical & Clinical Trial Dosing Paradigms
8.1 Clinical Trial Dosing
In published Phase I and Phase II human clinical studies of CJC-1295 (Teichman et al., 2006; Ionescu & Frohman, 2006), weight-based subcutaneous regimens ranged from 30 μg/kg to 120 μg/kg administered as single doses or on weekly to biweekly schedules, with the 60 μg/kg regimen commonly evaluated in adult GH deficiency and sleep-architecture studies.
8.2 Preclinical Dosing
In animal research protocols, published subcutaneous regimens include:
- Rats: 30–300 μg/kg administered subcutaneously (maximal responses at 100–300 μg/kg; Teichman et al. (2006)).
- Swine and Non-Human Primates: 60–300 μg/kg administered subcutaneously in single-dose and pharmacodynamic studies (Ionescu and Frohman (2006)); published comparative PK studies used 100 μg/kg.
8.3 Administration Route and Pharmacokinetics
Subcutaneous administration provides consistent bioavailability (approximately 70%) with peak plasma concentrations achieved 2–8 hours post-injection and terminal elimination half-lives of 4.2 to 6.9 days.
9. Storage and Stability
9.1 Lyophilized Peptide Storage
Lyophilized CJC-1295 demonstrates optimal stability when stored at −20 °C or below, protected from light and moisture (<2% degradation over 24 months). Refrigerated storage (2–8 °C) is acceptable for shorter durations (<5% degradation over 12 months). Vials should be equilibrated to ambient temperature in a desiccated environment prior to opening to prevent moisture condensation.
9.2 Reconstituted Solution Stability
Following reconstitution in sterile water or 0.9% sodium chloride, CJC-1295 solutions should be stored refrigerated at 2–8 °C and used within 14 days. Freezing of reconstituted solutions and repeated freeze-thaw cycles should be avoided to prevent peptide aggregation and potency loss.
9.3 Handling and Shipping Considerations
Shipping of lyophilized CJC-1295 should employ cold chain logistics with temperature monitoring. Upon receipt, the lyophilized powder should appear as a white to off-white cake or powder; any questionable materials should be verified by RP-HPLC and MS before experimental use.
10. Safety Considerations and Adverse Effects
10.1 Clinical Safety Profile
The clinical safety database for CJC-1295, while limited to early-phase studies, indicates generally good tolerability at studied doses. The most commonly reported adverse effects in clinical trials include mild, self-limiting injection site reactions (erythema, induration) occurring in 15–20% of subjects, transient facial flushing in 8–12% of subjects, and occasional headache (6–8% incidence).
10.2 Metabolic and Endocrine Effects
Metabolic safety assessments in clinical studies revealed no significant deterioration in fasting glucose, insulin sensitivity, HbA1c, or thyroid/adrenal/gonadal hormone panels at studied regimens.
10.3 Contraindications and Precautions
Active malignancy, proliferative diabetic retinopathy, pregnancy, and lactation represent standard exclusions in research protocols involving somatotropic axis modulation.
11. Literature Review and Key Publications
11.1 Key References
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 16968804
- Jetton TL, Lausier J, LaRock K, et al. Mechanisms of compensatory beta-cell growth in insulin-resistant rats: roles of Akt kinase. Diabetes. 2005;54(8):2294-2304. PMID: 16046294
- Alba M, Salvatori R. A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated growth hormone deficiency. Endocrinology. 2004;145(9):4134-4143. PMID: 15155574
- Thorner MO, Vance ML, Horvath E, et al. The anterior pituitary. In: Wilson JD, Foster DW, Kronenberg HM, et al., eds. Williams Textbook of Endocrinology. 9th ed. Philadelphia: WB Saunders; 1998:249-340.
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. PMID: 9861545
- Kopchick JJ, Andry JM. Growth hormone (GH), GH receptor, and signal transduction. Mol Genet Metab. 2000;71(1-2):293-314. PMID: 11001822
- Baumann GP. Growth hormone binding proteins. Proc Soc Exp Biol Med. 1993;202(4):392-400. PMID: 8437985
- Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol. 1998;140(1-2):19-24. PMID: 9722162
- Veldhuis JD, Keenan DM, Pincus SM. Motivations and methods for analyzing pulsatile hormone secretion. Endocr Rev. 2008;29(7):823-864. PMID: 18940916
12. Conclusion and Future Perspectives
CJC-1295 represents an engineered GHRH analog incorporating Drug Affinity Complex albumin-binding chemistry to extend biological half-life from minutes to days while preserving endogenous pulsatile GH secretion patterns. Preclinical and Phase I/II clinical investigations have characterized its receptor binding, pharmacokinetic scaling, and somatotropic effects across rodent, porcine, primate, and human models.
